172 related articles for article (PubMed ID: 16556037)
1. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Harrison CN
Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
3. New drugs in essential thrombocythemia and polycythemia vera.
Tefferi A; Elliott MA; Solberg LA; Silverstein MN
Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
6. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
7. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
Thiele J; Kvasnicka HM; Schmitt-Gräff A
Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
Petitt RM; Silverstein MN; Petrone ME
Semin Hematol; 1997 Jan; 34(1):51-4. PubMed ID: 9025162
[No Abstract] [Full Text] [Related]
9. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
10. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
11. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
Antelo ML; de Las Heras N; Gonzalez Porras JR; Kerguelen A; Raya JM
Expert Rev Hematol; 2015 Dec; 8(6):819-35. PubMed ID: 26368319
[TBL] [Abstract][Full Text] [Related]
12. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
13. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
14. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
Penka M; Schwarz J; Pavlík T; Indrák K; Doubek M; Dulícek P; Pospísilová D; Kissová J; Jonásová A; Jelínková P; Hlusí A; Schutzová M; Cerná O; Brychtová Y; Nováková L; Korístek Z; Segethová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Walterová L; Bodzásová C; Dusek L
Vnitr Lek; 2009 Nov; 55(11):I-XII. PubMed ID: 20017445
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
16. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
[TBL] [Abstract][Full Text] [Related]
17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Silver RT
Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
[TBL] [Abstract][Full Text] [Related]
19. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
20. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
Jantunen E; Penttilä K; Kuittinen T; Nousiainen T
Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
[No Abstract] [Full Text] [Related]
[Next] [New Search]